Pneumococcal infection, caused by the grampositive diplococcus Streptococcus pneumoniae, is the leading bacterial cause of adult community-acquired pneumonia requiring hospitalisation, accounting for about one-third of cases. Occasionally, it invades normally sterile areas, resulting in invasive pneumococcal disease with complications such as empyema, bacteraemia, or meningitis. Mortality among adults hospitalised for pneumococcal disease in Singapore ranges from 18.5-26.1 percent. Individuals at the extremes of age, with multiple chronic conditions, or who are immunocompromised are at higher risk of developing severe disease. The 20-valent pneumococcal conjugate vaccine (PCV20) is safe and effective against most circulating Streptococcus pneumoniae serotypes and is approved for adults aged 19 and older in Singapore. It covers most serotypes included in the older 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23). A single dose of PCV20 is recommended for adults aged 65 and older without comorbid conditions and adults aged 19 and older with underlying medical conditions, replacing the need for sequential PCV13 and PPSV23 vaccinations. Patients with prior PPSV23 or PCV13 should be given PCV20 at least one year after PPSV23/PCV13. PCV20 can be co-administered with inactivated influenza or COVID-19 (BNT162b2) vaccines.